Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy - Wikidata - awgldk - TriplyDB

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy

http://www.wikidata.org/entity/Q34674928

about

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines Studying Cellular Signal Transduction with OMIC Technologies Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis The role of Src in solid tumors Recent advances in the molecular understanding of glioblastoma Identifying druggable disease-modifying gene products Latent bone metastasis in breast cancer tied to Src-dependent survival signals A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Cyclin G2 promotes hypoxia-driven local invasion of glioblastoma by orchestrating cytoskeletal dynamics.Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.A cell-penetrating peptide based on the interaction between c-Src and connexin43 reverses glioma stem cell phenotype.A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells.Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases.EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.The kinase Mirk is a potential therapeutic target in osteosarcoma.Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib A chemical and phosphoproteomic characterization of dasatinib action in lung cancer Molecular targeting of glioblastoma: Drug discovery and therapies Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.HIF-1 and c-Src mediate increased glucose uptake induced by endothelin-1 and connexin43 in astrocytes Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.Sequential multiplex analyte capturing for phosphoprotein profiling.Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study A Novel Phosphopeptide Microarray Based Interactome Map in Breast Cancer Cells Reveals Phosphoprotein-GRB2 Cell Signaling Networks.Pathway inhibition: emerging molecular targets for treating glioblastoma.Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.A pharmacogenomic method for individualized prediction of drug sensitivity A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies

P2860

Q23058134-5DC60978-9264-41FF-9A3A-EB50E77C0D44 Q24289429-05B99518-AF92-4F95-BF87-9AD0F6FC3F98 Q24299210-C64D7FF4-6B99-4ACA-A44D-FCECCD9DF769 Q24306274-65C165AA-7B32-4669-84AC-4784920C4C7E Q24616659-9F6FF255-BE59-45FE-AD82-1069A905603A Q24632928-9A719D9D-7251-46D3-ADB8-10B812040618 Q24646409-E000F23E-A4CE-4C57-B6AA-FC0D6D15193F Q24648828-294C626C-16FF-45DB-9532-CADDB2E19CDE Q27851660-F080EF1D-237F-419E-A0DA-0B3760F39FE7 Q27851720-7CE16F2F-0B74-405A-A40D-B44538399F47 Q28253621-229A0669-EE5D-4688-8560-CD1ED29F736D Q28535249-D5A075C1-5CEA-412E-89F8-D7579BDAC994 Q28771755-C8208D89-1B57-4766-ABDF-D983C8EC7972 Q28829017-C5F84A39-FAA3-4D15-A515-E92407FA8DB0 Q29617359-5B24070E-1258-4F0F-95D1-EF914F4F76F2 Q30009513-E792F91C-E9F7-49B1-9F94-89A6876B3BE0 Q30361219-A5F0FBB2-9CD5-48CE-9062-15AFDDC113C0 Q30579545-C05BFE73-B29A-459A-A597-9AAECEC6E93A Q30981853-FA7CAF44-61E5-4FDB-8663-C640189A17D8 Q31138564-982914C0-A81A-4F24-881D-8FDDFEBCA489 Q33403967-092883D5-3D2E-4E67-8F2B-B7FFF5CC581A Q33521423-9322177B-5F48-4A82-8D61-412019DA859C Q33655352-820D44D5-92DE-4896-AB8E-04F018EE2723 Q33742159-60C4CCBA-5E8E-4D62-A9E4-67F2C38F8079 Q33911283-8B3402E7-C941-4E77-BD7D-5CFE6DC2AFD5 Q33992432-67B6A16C-F5AB-4FFB-947D-4EE88801562D Q34017103-07442DF9-8741-4AB7-9A8C-9BB6B5265BF3 Q34121339-B25F90D2-F844-4274-AB62-C2BE49532B24 Q34182724-1E477FF9-53F5-4CB3-8AD1-DBF57F011CFB Q34264571-C77E3E69-4488-4AA4-9ADD-ABF3732A4FD6 Q34320767-1E4A0D69-9D70-4B93-832A-0F254201C7C1 Q34606869-B4C2861F-7C9C-407F-8E55-FF3BC7B3D7F4 Q34658293-240CEA86-01BF-4785-B851-16439759D884 Q34797435-1AD98720-5DFD-4ED6-B775-C47BD34C798A Q35021359-F0FA6421-A8FD-43E2-93C2-78600B4680F2 Q35070978-F2065098-DE35-4F50-9113-C4F44FB4E7FB Q35176386-E1EA3531-EE1A-4BA4-96AB-22AA651F91B9 Q35263202-59C10C25-B5DA-42C0-BCBD-E3F4E1366E56 Q35408594-A09FF636-AE4A-46C1-9CBD-9FB8CEE1EFE9 Q35539318-C0D621E3-0FDD-4BDE-BB96-F27D41A12766

P2860

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy

http://www.wikidata.org/entity/Q34674928

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Bead-based profiling of tyrosi ...... arget for glioblastoma therapy

@ast

Bead-based profiling of tyrosi ...... arget for glioblastoma therapy

@en

Bead-based profiling of tyrosi ...... arget for glioblastoma therapy

@nl

type

label

Bead-based profiling of tyrosi ...... arget for glioblastoma therapy

@ast

Bead-based profiling of tyrosi ...... arget for glioblastoma therapy

@en

Bead-based profiling of tyrosi ...... arget for glioblastoma therapy

@nl

prefLabel

Bead-based profiling of tyrosi ...... arget for glioblastoma therapy

@ast

Bead-based profiling of tyrosi ...... arget for glioblastoma therapy

@en

Bead-based profiling of tyrosi ...... arget for glioblastoma therapy

@nl

P1433

Q34674928-16860974-AF39-41BA-BFC9-771C121ABB1A

P1476

Q34674928-4C7886B6-699E-477C-9A16-3AC70C04C61E

P2093

Q34674928-0E0EB3B0-B092-4D56-9F41-DB6ECB707D80

Q34674928-1871FD2E-CEBC-4442-A812-209C8AEC46B0

Q34674928-3A33CE39-82D1-42F5-B1A2-B6DB56E9214B

Q34674928-4A79F128-7233-4605-8E16-C878CD312F60

Q34674928-5C32C9D0-8A01-4674-A11B-9A203F171723

Q34674928-7FDCE042-2182-40CB-8191-8D53A89D55BC

Q34674928-808848FC-3952-417E-B0A6-C7425F5CD625

Q34674928-8EE91305-A2E6-4B22-9C1B-9AC7A4F0E7C7

Q34674928-9E0F7ED1-D3D9-46CF-8A37-9F8723E19069

Q34674928-C7ECB37B-ACF7-4008-BDBB-C32B52A5F532

P2860

Q34674928-07EF77A5-AE72-445D-B029-F0F3FD51762F

Q34674928-0A34A978-324B-40DD-9D5A-86784DB87C3F

Q34674928-13AACFF5-9EF8-4068-A3B3-78D4AAC19CF8

Q34674928-2354E3F9-2F2E-4D29-9616-040D92E18B84

Q34674928-254F6EFB-15B2-43AD-8F7D-97DD2F65D45F

Q34674928-33CBF340-9112-4852-ADB3-F2458D940E98

Q34674928-3A362EDB-D958-4F8C-94C3-688D1858A81C

Q34674928-3C67EEC2-71BF-4373-9FED-D944B31490AE

Q34674928-419F15C6-BC51-41B6-9384-9918DE8C52C8

Q34674928-4DAA2059-5B4E-4834-BEA6-016999117846

P2888

Q34674928-D4605292-1AA2-4CEC-8328-79BB2732AA0D

P304

Q34674928-55ABB55C-D30C-4B44-BAB6-D2305A1D79ED

P31

Q34674928-A38FAE92-FCBC-4F86-B1DF-B606AE5F0940

P356

Q34674928-05702135-B41B-4CC4-B7AD-823941463438

P433

Q34674928-FD9E14AA-D2EF-4449-AF06-4F640E9E7CD8

P478

Q34674928-0C45E793-71A4-4D69-9D0D-65FA0E3124B8

P50

Q34674928-05869D9A-96D4-465D-909D-41B9BEAE602D

Q34674928-51DA9ED6-D719-4465-9755-F042C673A95E

Q34674928-ADDA06EF-4659-45AD-B7E2-E03501350ADD

Q34674928-E9930A6A-048C-410B-91B6-D5ADDA89E613

Q34674928-F94EBD6B-95E0-447B-B936-929DD3D1F34F

P577

Q34674928-2D583D8D-B9E4-495F-86D6-652669B34BC5

P5875

Q34674928-982C1474-F1B1-4748-ACEE-F950DB1E2700

P698

Q34674928-39299245-EABC-41DD-A98F-895A277065C1

P921

Q34674928-D31D7BE6-F4EB-4A01-A8CC-9A52A2BDAC91

P932

Q34674928-1C288E93-77BC-4248-9C64-717BF9CD17C8

P356

P1433

Nature Biotechnology

P1476

Bead-based profiling of tyrosi ...... arget for glioblastoma therapy

@en

P2093

Bina Julian

http://www.w3.org/2001/XMLSchema#string

David N Louis

http://www.w3.org/2001/XMLSchema#string

Haley Hieronymus

http://www.w3.org/2001/XMLSchema#string

Ingo K Mellinghoff

http://www.w3.org/2001/XMLSchema#string

Jinyan Du

http://www.w3.org/2001/XMLSchema#string

Linda M Liau

http://www.w3.org/2001/XMLSchema#string

Massimo Loda

http://www.w3.org/2001/XMLSchema#string

Melissa Burns

http://www.w3.org/2001/XMLSchema#string

Paula Bernasconi

http://www.w3.org/2001/XMLSchema#string

Phioanh Nghiemphu

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoaffinity profiling of tyrosine phosphorylation in cancer cells

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Structural organization of the bcr gene and its role in the Ph' translocation

Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

Overriding imatinib resistance with a novel ABL kinase inhibitor

Src family kinases, key regulators of signal transduction.

P2888

P304

77-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT.1513

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Stephen P. Finn

Karl R. Clauser

P577

2008-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23680436

http://www.w3.org/2001/XMLSchema#string

P698

19098899

http://www.w3.org/2001/XMLSchema#string

P921

phosphorylation

P932

3057643

http://www.w3.org/2001/XMLSchema#string